ADC Therapeutics SA
General ticker "ADCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $276.2M (TTM average)
ADC Therapeutics SA follows the US Stock Market performance with the rate: 54.0%.
Estimated limits based on current volatility of 8.3%: low 3.59$, high 4.24$
Factors to consider:
- Total employees count: 273 as of 2023
- US accounted for 99.3% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Product liability, Operational and conduct risks, Regulatory and compliance, Supply chain disruptions, Manufacturing risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.29$, 3.81$]
- 2025-12-31 to 2026-12-31 estimated range: [1.13$, 3.40$]
Financial Metrics affecting the ADCT estimates:
- Positive: with PPE of -1.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -63.55 <= 0.33
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.44 > -0.66
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of -62.94 <= 18.93
Short-term ADCT quotes
Long-term ADCT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $209.91MM | $69.56MM | $70.84MM |
| Operating Expenses | $333.25MM | $235.54MM | $201.49MM |
| Operating Income | $-123.34MM | $-165.99MM | $-130.65MM |
| Non-Operating Income | $-23.47MM | $-29.43MM | $-27.03MM |
| Interest Expense | $36.73MM | $46.33MM | $50.21MM |
| R&D Expense | $186.46MM | $127.13MM | $109.63MM |
| Income(Loss) | $-146.82MM | $-195.42MM | $-157.68MM |
| Taxes | $0.23MM | $39.11MM | $0.17MM |
| Other Income(Loss) | $-10.08MM | $-5.53MM | $0.00MM |
| Profit(Loss)* | $-157.13MM | $-240.05MM | $-157.85MM |
| Stockholders Equity | $79.45MM | $-148.25MM | $-202.64MM |
| Inventory | $12.07MM | $16.18MM | $18.39MM |
| Assets | $490.86MM | $354.78MM | $321.98MM |
| Operating Cash Flow | $-138.31MM | $-118.69MM | $-123.83MM |
| Capital expenditure | $0.69MM | $3.22MM | $0.87MM |
| Investing Cash Flow | $-0.69MM | $-3.22MM | $-0.87MM |
| Financing Cash Flow | $-0.90MM | $73.88MM | $97.05MM |
| Earnings Per Share** | $-2.01 | $-2.94 | $-1.62 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.